Welcome to our dedicated page for 180 Life Sciences SEC filings (Ticker: ATNFW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
180 life sciences corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. its product development platforms in phase iib/iii clinical trials include fibrosis and anti-tnf platform, which focuses on fibrosis and anti-tumor necrosis factors; synthetic cannabidiol (cbd) analogs platform, which are man-made derivatives of cbd; and a7nachr platform, which focuses on alpha 7 nicotinic acetylcholine receptor. the company is headquartered in menlo park, california.Blair Jordan, Chief Executive Officer of 180 Life Sciences Corp. (ATNFW), filed Schedule 13D/A Amendment No. 4 reporting that his beneficial ownership has dropped to 2,298,742 shares, or 1.5 % of the 154.0 M shares outstanding as of 5 Aug 2025, taking him below the 5 % reporting threshold on 4 Aug 2025.
Holdings include: (i) 160,000 directly held shares; (ii) 167,576 restricted shares issued 17 Jun 2025 and fully vested 12 Jul 2025; (iii) 410,000 vested options at $0.929; and (iv) irrevocable voting proxies over 1,561,166 additional shares. On 29 Jul 2025 Jordan’s consulting entity received a conditional grant of 3,908,986 options at $2.92, exercisable only after shareholder approval of the 2025 Supplemental Option Plan by 29 Jul 2026 and the closing of a related securities purchase agreement (completed 4 Aug 2025).
The amendment also records accelerated vesting of equity awards approved by the Board on 17 Jun and 12 Jul 2025. Jordan states the securities are held for investment purposes and, while he may buy or sell shares, he currently has no plans for mergers, asset sales, board changes or other corporate actions.
180 Life Sciences Corp. (symbol ATNFW) filed a Form S-8 to register 5,000,000 new common shares for equity compensation programs:
- 4,000,000 additional shares for the Fourth Amended & Restated 2022 Omnibus Incentive Plan
- 1,000,000 shares for the newly adopted 2025 Option Incentive Plan
FAQ
What is the current stock price of 180 Life Sciences (ATNFW)?
